<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731469</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-131-1</org_study_id>
    <nct_id>NCT02731469</nct_id>
  </id_info>
  <brief_title>Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers</brief_title>
  <official_title>Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-131-1 is an Open-Label Clinical Study of the Pharmacokinetics, Pharmacodynamics,
      Tolerability, Safety and Immunogenicity of Single Ascending Doses of BCD-131 in Healthy
      Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BCD-131 is novel drug product of pegylated darbepoetin alfa.

      Clinical trial BCD-131-1 will be conducted in two stages:

      Stage I is an open-label, non-randomized clinical study of pharmacokinetics,
      pharmacodynamics, tolerability, safety and immunogenicity of BCD-131 given to healthy
      volunteers at ascending doses (Phase 1, a traditional &quot;3+3&quot; design).

      Also, the PK and PD parameters of the closest analogues of BCD-131 (Mircera and Aranesp)
      given as subcutaneous injections at therapeutic doses will be evaluated.

      Stage II aims to further evaluate pharmacokinetics, pharmacodynamics and safety of
      subcutaneous and intravenous injections of BCD-131 at a dose which ensures PD effects similar
      to those of the closest analogues (Mircera, Aranesp) given as subcutaneous injections at
      therapeutic doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (0-1176 Hours)</measure>
    <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose</time_frame>
    <description>Area under curve (AUC) &quot;concentration - time&quot; from 0 hours to 1176 hours and to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
    <description>Maximal concentration of drug in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
    <description>Time from 9 hours to time of maximal concentration of drug in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
    <description>Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kel</measure>
    <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
    <description>Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of BCD-131</measure>
    <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
    <description>Clearance of BCD-131 in blood after single injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-1176 Hours) - Reticulocytes</measure>
    <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
    <description>Area under effect curve (AUEC) &quot;absolute reticulocyte count - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC (0-1176 Hours) - Hemoglobin</measure>
    <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
    <description>Area under effect curve (AUEC) &quot;hemoglobin - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC-Emax - Reticulocytes</measure>
    <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
    <description>Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AC-Emax - Hemoglobin</measure>
    <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
    <description>Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale</measure>
    <time_frame>intraoperative</time_frame>
    <description>visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events</measure>
    <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
    <description>Total incidence of adverse events (AE)/ serious adverse events (SAE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Local Reactions</measure>
    <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
    <description>Incidence of administration site reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AE/SAE 3-4 Grade CTCAE</measure>
    <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
    <description>Incidence of Grade 3-4 AEs and SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Early Withdrawal Due to AE</measure>
    <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
    <description>Frequency of early withdrawals due to AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Binding Antibodies to BCD-131</measure>
    <time_frame>0, day 50 post-dose</time_frame>
    <description>Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Reticulocyte Count</condition>
  <arm_group>
    <arm_group_label>BCD-131, 0.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.05 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 0.15 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.15 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 0.40 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.40 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 1.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 1.05 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 1.70 mcg/kg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 1.70 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 2.25 mcg/kg SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 2.25 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, 4.45 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 4.45 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mircera®, 1.20 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers will receive Mircera in a dose 1.20 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aranesp®, 0.45 mcg/kg subcutaneously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in a dose 0.45 mcg/kg subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, optimal dose, intravenously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial intravenously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BCD-131, optimal dose, subcutaneously</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers will receive BCD-131 in optimal dose determined on first stage of clinical trial subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-131</intervention_name>
    <arm_group_label>BCD-131, 0.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 0.15 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 0.40 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 1.05 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, 1.70 mcg/kg SC</arm_group_label>
    <arm_group_label>BCD-131, 2.25 mcg/kg SC</arm_group_label>
    <arm_group_label>BCD-131, 4.45 mcg/kg subcutaneously</arm_group_label>
    <arm_group_label>BCD-131, optimal dose, intravenously</arm_group_label>
    <arm_group_label>BCD-131, optimal dose, subcutaneously</arm_group_label>
    <other_name>pegylated darbepoetin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mircera®</intervention_name>
    <arm_group_label>Mircera®, 1.20 mcg/kg subcutaneously</arm_group_label>
    <other_name>Methoxy polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aranesp®</intervention_name>
    <arm_group_label>Aranesp®, 0.45 mcg/kg subcutaneously</arm_group_label>
    <other_name>darbepoetin alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signing of the Informed Consent Form;

          2. Male sex;

          3. Age of 18 to 45 years, inclusive;

          4. BMI within normal limits (18.5-24.9 kg/m2);

          5. Healthy patients, which is proved by their medical history, physical examination and
             laboratory findings:

               -  No clinically significant abnormalities of circulatory, respiratory, nervous,
                  hematopoietic, endocrine and digestive systems, liver and kidneys in the past
                  medical history and at screening;

               -  No history of cardiovascular disorders or thyroid disorders;

               -  No history of hematologic disorders, including but not limited to any type of
                  anemia, myelodysplastic syndrome, blood cancers, hemolytic syndrome,
                  hemoglobinopathies, coagulopathies;

               -  CBC results within normal limits, including:

                    -  Hemoglobin within 132-173 g/L;

                    -  Hematocrit (based on CBC results) within 39-49%;

                    -  Platelet count within 150-400*109/L;

                    -  Absolute reticulocyte count within 30.4-93.5 * 109/L;

               -  Blood biochemistry and urinalysis results within normal limits;

               -  Serum ferritin within 20-250 µg/L;

               -  Serum endogenous erythropoietin within 4.3-29.0 MIU/mL;

               -  Hemodynamic parameters within normal limits: systolic blood pressure within
                  100-139 mmHg; diastolic blood pressure within 60-90 mmHg; heart rate within 50-90
                  bpm;

               -  No history of chronic infections (tuberculosis) or chronic inflammation;

               -  No hepatitis B or C, HIV, or syphilis;

               -  No acute infections within 4 weeks prior to inclusion in the study;

               -  No psychiatric disorders and other conditions (including depression) that can
                  interfere with the volunteer's ability to follow the study protocol;

               -  Well-being (in the volunteer's opinion) within 30 days prior to inclusion in the
                  study;

          6. No history of or current (at baseline) alcohol or drug abuse;

          7. Ability of the volunteer, in the investigator's opinion, to follow the study protocol
             procedures;

          8. Willingness of volunteers and their sexual partners with preserved reproductive
             potential to use reliable contraception within 2 weeks before inclusion in the study
             and up to 7 weeks after the injection of the test product. This criterion is not
             applicable to subjects who underwent surgical sterilization. Reliable methods of
             contraception include one barrier method in combination with one of the following
             methods: spermicides, intrauterine device/oral contraceptives (for sexual partners).

          9. Willingness of volunteers to avoid alcohol intake within 24 hours before and 8 days
             after each injection of the test drug;

        Exclusion Criteria:

          1. History of treatment with erythropoietins or any other ESAs;

          2. Acute bleeding, blood/plasma donation or blood transfusion within 2 months before
             inclusion in the study;

          3. History of chronic bleeding;

          4. Standard laboratory and instrumental findings outside normal limits at screening;

          5. History of allergies (anaphylactic shock or multiple drug allergy syndrome);

          6. Known allergy or intolerance to any components of the investigational product;

          7. Major surgery within 30 days prior to screening, or surgery being scheduled for any
             time during the study;

          8. Impossibility to install a venous catheter for blood sampling (e.g. because of skin
             disorders at the sites of venipuncture);

          9. Diseases or other conditions that can interfere with the pharmacokinetics of the
             investigational drug (e.g. chronic liver, kidney, blood, circulatory system, lung or
             neuroendocrine diseases, including diabetes mellitus and others);

         10. History of fever of 40 °C or more;

         11. History of elevated hepatic transaminases (above 2.5xULN);

         12. Episodes of thrombosis and/or thromboembolia in past medical history (myocardial
             infarction, stroke, transient ischemic attacks, deep vein thrombosis, pulmonary
             embolism within 6 months prior to inclusion in the study) as well as an increased risk
             of deep vein thrombosis;

         13. History of epileptic attacks or seizures;

         14. History or current (at screening) depression, suicidal thoughts/ attempts;

         15. Regular oral or parenteral use of any medications including over-the-counter drugs,
             vitamins and nutritional additives within 2 weeks before a scheduled injection of the
             test drug;

         16. Use of drugs, including OTC products, that significantly affect the hemodynamics,
             hepatic function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days
             before a scheduled injection of the test drug;

         17. Vaccination within 4 weeks before a scheduled injection of the test drug;

         18. Smoking more than 10 cigarettes per day;

         19. Consumption of more than 10 portions of alcohol per week (one portion equals to 0.5 L
             of beer, 200 mL of wine or 50 mL of ethanol) or a history of alcohol, drug or
             medication abuse;

         20. Participation in other clinical studies within 1 month before screening or
             simultaneous participation in another clinical study;

         21. Previous participation in this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>JCS BIOCAD</affiliation>
  </overall_official>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>April 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02731469/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 21, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT02731469/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P2">
          <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P3">
          <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P4">
          <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P5">
          <title>BCD-131, 1.70 mcg/kg SC</title>
          <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P6">
          <title>BCD-131, 2.25 mcg/kg SC</title>
          <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P7">
          <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="P8">
          <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
        </group>
        <group group_id="P9">
          <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
        </group>
        <group group_id="P10">
          <title>BCD-131, Optimal Dose, Intravenously</title>
          <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
        </group>
        <group group_id="P11">
          <title>BCD-131, Optimal Dose, Subcutaneously</title>
          <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B2">
          <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B3">
          <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B4">
          <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B5">
          <title>BCD-131, 1.70 mcg/kg SC</title>
          <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B6">
          <title>BCD-131, 2.25 mcg/kg SC</title>
          <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B7">
          <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="B8">
          <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
        </group>
        <group group_id="B9">
          <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
        </group>
        <group group_id="B10">
          <title>BCD-131, Optimal Dose, Intravenously</title>
          <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
        </group>
        <group group_id="B11">
          <title>BCD-131, Optimal Dose, Subcutaneously</title>
          <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="3"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="21" upper_limit="25"/>
                    <measurement group_id="B2" value="26" lower_limit="22" upper_limit="36"/>
                    <measurement group_id="B3" value="30" lower_limit="23" upper_limit="40"/>
                    <measurement group_id="B4" value="32" lower_limit="23" upper_limit="36"/>
                    <measurement group_id="B5" value="26" lower_limit="26" upper_limit="27"/>
                    <measurement group_id="B6" value="25" lower_limit="22" upper_limit="32"/>
                    <measurement group_id="B7" value="25" lower_limit="22" upper_limit="26"/>
                    <measurement group_id="B8" value="28" lower_limit="22" upper_limit="31"/>
                    <measurement group_id="B9" value="28" lower_limit="25" upper_limit="31"/>
                    <measurement group_id="B10" value="24" lower_limit="23" upper_limit="29"/>
                    <measurement group_id="B11" value="25" lower_limit="25" upper_limit="27"/>
                    <measurement group_id="B12" value="26" lower_limit="23" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-1176 Hours)</title>
        <description>Area under curve (AUC) &quot;concentration - time&quot; from 0 hours to 1176 hours and to infinity</description>
        <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-1176 Hours)</title>
          <description>Area under curve (AUC) &quot;concentration - time&quot; from 0 hours to 1176 hours and to infinity</description>
          <units>pg*hr/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206974.500" lower_limit="144988.500" upper_limit="485443.500"/>
                    <measurement group_id="O2" value="657417.000" lower_limit="598401.500" upper_limit="666088.500"/>
                    <measurement group_id="O3" value="827904.750" lower_limit="362302.000" upper_limit="1179816.500"/>
                    <measurement group_id="O4" value="1360020.000" lower_limit="424094.000" upper_limit="1427990.750"/>
                    <measurement group_id="O5" value="1314197.750" lower_limit="64430.000" upper_limit="1465335.500"/>
                    <measurement group_id="O6" value="3202606.500" lower_limit="2173496.250" upper_limit="4300376.000"/>
                    <measurement group_id="O7" value="5220198.750" lower_limit="4658082.250" upper_limit="5328878.250"/>
                    <measurement group_id="O8" value="688124.000" lower_limit="478496.000" upper_limit="1252376.250"/>
                    <measurement group_id="O9" value="94628.375" lower_limit="49807.250" upper_limit="113412.500"/>
                    <measurement group_id="O10" value="6382389.188" lower_limit="4818041.5" upper_limit="6826251.75"/>
                    <measurement group_id="O11" value="2089193.125" lower_limit="789943" upper_limit="2926898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximal concentration of drug in blood after single injection</description>
        <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximal concentration of drug in blood after single injection</description>
          <units>picogram per ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="585.000" lower_limit="503.000" upper_limit="744.000"/>
                    <measurement group_id="O2" value="1035.000" lower_limit="854.000" upper_limit="1761.000"/>
                    <measurement group_id="O3" value="2248.000" lower_limit="1457.000" upper_limit="2566.000"/>
                    <measurement group_id="O4" value="3634.000" lower_limit="2924.000" upper_limit="4954.000"/>
                    <measurement group_id="O5" value="3541.000" lower_limit="150.000" upper_limit="4110.000"/>
                    <measurement group_id="O6" value="12023.000" lower_limit="6863.000" upper_limit="12243.000"/>
                    <measurement group_id="O7" value="15433.000" lower_limit="13286.000" upper_limit="16404.000"/>
                    <measurement group_id="O8" value="2298.000" lower_limit="1849.000" upper_limit="6867.000"/>
                    <measurement group_id="O9" value="964.500" lower_limit="870.000" upper_limit="1229.000"/>
                    <measurement group_id="O10" value="87526.5" lower_limit="69859" upper_limit="93090"/>
                    <measurement group_id="O11" value="10588" lower_limit="3713" upper_limit="11692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax</title>
        <description>Time from 9 hours to time of maximal concentration of drug in blood after single injection</description>
        <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Time from 9 hours to time of maximal concentration of drug in blood after single injection</description>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216.000" lower_limit="96.000" upper_limit="504.000"/>
                    <measurement group_id="O2" value="168.000" lower_limit="72.000" upper_limit="504.000"/>
                    <measurement group_id="O3" value="96.000" lower_limit="8.000" upper_limit="96.000"/>
                    <measurement group_id="O4" value="72.000" lower_limit="48.000" upper_limit="72.000"/>
                    <measurement group_id="O5" value="72.000" lower_limit="48.000" upper_limit="168.000"/>
                    <measurement group_id="O6" value="120.000" lower_limit="96.000" upper_limit="168.000"/>
                    <measurement group_id="O7" value="96.000" lower_limit="72.000" upper_limit="96.000"/>
                    <measurement group_id="O8" value="48.000" lower_limit="48.000" upper_limit="72.000"/>
                    <measurement group_id="O9" value="36.000" lower_limit="8.000" upper_limit="36.000"/>
                    <measurement group_id="O10" value="0.75" lower_limit="0.5" upper_limit="1"/>
                    <measurement group_id="O11" value="84" lower_limit="72" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2</title>
        <description>Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible</description>
        <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
        <population>the calculation of the half-life in group 0,15 mcg/kg was not carried out, due to the lack of a linear terminal phase of elimination in volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2</title>
          <description>Half-life of drug in blood after single injection. In the coрort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of T1 / 2 was not possible</description>
          <population>the calculation of the half-life in group 0,15 mcg/kg was not carried out, due to the lack of a linear terminal phase of elimination in volunteers</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.094" lower_limit="322.094" upper_limit="322.094"/>
                    <measurement group_id="O3" value="377.272" lower_limit="281.082" upper_limit="473.461"/>
                    <measurement group_id="O4" value="212.231" lower_limit="212.231" upper_limit="212.231"/>
                    <measurement group_id="O5" value="416.482" lower_limit="326.648" upper_limit="506.316"/>
                    <measurement group_id="O6" value="191.477" lower_limit="145.071" upper_limit="495.813"/>
                    <measurement group_id="O7" value="181.310" lower_limit="168.649" upper_limit="186.681"/>
                    <measurement group_id="O8" value="114.855" lower_limit="105.888" upper_limit="256.031"/>
                    <measurement group_id="O9" value="79.473" lower_limit="44.619" upper_limit="104.605"/>
                    <measurement group_id="O10" value="116.125" lower_limit="70.7" upper_limit="120.38"/>
                    <measurement group_id="O11" value="182.392" lower_limit="123.71" upper_limit="197.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kel</title>
        <description>Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible</description>
        <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
        <population>the calculation of the Kel in group &quot;0,15 mcg/kg&quot; was not carried out, due to the lack of a linear terminal phase of elimination in volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Kel</title>
          <description>Elimination rate constant of drug in blood after single injection. In the cohort BCD-131 0,15 mcg/kg due to the absence of a linear terminal elimination phase in volunteers, the calculation of Kel was not possible</description>
          <population>the calculation of the Kel in group &quot;0,15 mcg/kg&quot; was not carried out, due to the lack of a linear terminal phase of elimination in volunteers</population>
          <units>fraction per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002152" lower_limit="0.002152" upper_limit="0.002152"/>
                    <measurement group_id="O3" value="0.001965" lower_limit="0.001464" upper_limit="0.002466"/>
                    <measurement group_id="O4" value="0.003266" lower_limit="0.003266" upper_limit="0.003266"/>
                    <measurement group_id="O5" value="0.001746" lower_limit="0.001369" upper_limit="0.002122"/>
                    <measurement group_id="O6" value="0.003620" lower_limit="0.001398" upper_limit="0.004778"/>
                    <measurement group_id="O7" value="0.003823" lower_limit="0.003713" upper_limit="0.004110"/>
                    <measurement group_id="O8" value="0.006057" lower_limit="0.003734" upper_limit="0.006549"/>
                    <measurement group_id="O9" value="0.009019" lower_limit="0.006697" upper_limit="0.019655"/>
                    <measurement group_id="O10" value="0.005977" lower_limit="0.003424" upper_limit="0.006196"/>
                    <measurement group_id="O11" value="0.003828" lower_limit="0.001367" upper_limit="0.00415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of BCD-131</title>
        <description>Clearance of BCD-131 in blood after single injection</description>
        <time_frame>0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of BCD-131</title>
          <description>Clearance of BCD-131 in blood after single injection</description>
          <units>ml per hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.393" lower_limit="8.446" upper_limit="24.140"/>
                    <measurement group_id="O2" value="16.200" lower_limit="15.313" upper_limit="21.808"/>
                    <measurement group_id="O3" value="33.337" lower_limit="24.411" upper_limit="83.908"/>
                    <measurement group_id="O4" value="54.043" lower_limit="48.530" upper_limit="225.304"/>
                    <measurement group_id="O5" value="92.812" lower_limit="91.843" upper_limit="1820.580"/>
                    <measurement group_id="O6" value="65.259" lower_limit="46.682" upper_limit="88.567"/>
                    <measurement group_id="O7" value="51.774" lower_limit="51.147" upper_limit="57.320"/>
                    <measurement group_id="O8" value="108.993" lower_limit="59.886" upper_limit="156.741"/>
                    <measurement group_id="O9" value="332.263" lower_limit="304.017" upper_limit="602.322"/>
                    <measurement group_id="O10" value="29.84" lower_limit="24.293" upper_limit="30.734"/>
                    <measurement group_id="O11" value="136.391" lower_limit="48.481" upper_limit="202.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC (0-1176 Hours) - Reticulocytes</title>
        <description>Area under effect curve (AUEC) &quot;absolute reticulocyte count - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
        <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC (0-1176 Hours) - Reticulocytes</title>
          <description>Area under effect curve (AUEC) &quot;absolute reticulocyte count - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
          <units>cells (10^9) * hr/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10568.04" lower_limit="10107.60" upper_limit="10940.76"/>
                    <measurement group_id="O2" value="348.000" lower_limit="144.000" upper_limit="1980.000"/>
                    <measurement group_id="O3" value="2868.000" lower_limit="2664.000" upper_limit="17556.00"/>
                    <measurement group_id="O4" value="11004.00" lower_limit="6006.000" upper_limit="13416.00"/>
                    <measurement group_id="O5" value="14481.60" lower_limit="10366.80" upper_limit="15530.40"/>
                    <measurement group_id="O6" value="25512.00" lower_limit="16476.00" upper_limit="30355.20"/>
                    <measurement group_id="O7" value="69120.00" lower_limit="46183.20" upper_limit="81511.20"/>
                    <measurement group_id="O8" value="10269.72" lower_limit="3121.200" upper_limit="16310.88"/>
                    <measurement group_id="O9" value="14223.60" lower_limit="8736.000" upper_limit="21257.28"/>
                    <measurement group_id="O10" value="21370.44" lower_limit="18081.6" upper_limit="22724.88"/>
                    <measurement group_id="O11" value="13129.2" lower_limit="4432.56" upper_limit="15072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC (0-1176 Hours) - Hemoglobin</title>
        <description>Area under effect curve (AUEC) &quot;hemoglobin - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
        <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC (0-1176 Hours) - Hemoglobin</title>
          <description>Area under effect curve (AUEC) &quot;hemoglobin - time&quot; from 0 to 1176 hours post-dose after single injection of study drug</description>
          <units>gr*hr/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="864.00" lower_limit="528.00" upper_limit="2460.00"/>
                    <measurement group_id="O2" value="216.00" lower_limit="0.00" upper_limit="1260.00"/>
                    <measurement group_id="O3" value="1992.00" lower_limit="1152.00" upper_limit="3864.00"/>
                    <measurement group_id="O4" value="4752.00" lower_limit="2688.00" upper_limit="6924.00"/>
                    <measurement group_id="O5" value="1548.00" lower_limit="1320.00" upper_limit="10128.00"/>
                    <measurement group_id="O6" value="1392.00" lower_limit="660.00" upper_limit="23460.00"/>
                    <measurement group_id="O7" value="3516.00" lower_limit="2904.00" upper_limit="4248.00"/>
                    <measurement group_id="O8" value="3492.00" lower_limit="720.00" upper_limit="6156.00"/>
                    <measurement group_id="O9" value="3120.00" lower_limit="2112.00" upper_limit="4320.00"/>
                    <measurement group_id="O10" value="4008" lower_limit="2340" upper_limit="4044"/>
                    <measurement group_id="O11" value="4632" lower_limit="2448" upper_limit="4812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AC-Emax - Reticulocytes</title>
        <description>Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug</description>
        <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>AC-Emax - Reticulocytes</title>
          <description>Absolute maximum of reticulocyte count (AC-Emax - reticulocytes) after single injection of study drug</description>
          <units>10e9 reticulocytes per liter&quot;</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.65" lower_limit="17.15" upper_limit="31.34"/>
                    <measurement group_id="O2" value="6.00" lower_limit="6.00" upper_limit="22.00"/>
                    <measurement group_id="O3" value="13.00" lower_limit="11.00" upper_limit="34.00"/>
                    <measurement group_id="O4" value="27.00" lower_limit="12.00" upper_limit="28.00"/>
                    <measurement group_id="O5" value="20.68" lower_limit="17.00" upper_limit="26.00"/>
                    <measurement group_id="O6" value="112.00" lower_limit="81.00" upper_limit="132.00"/>
                    <measurement group_id="O7" value="110.00" lower_limit="69.00" upper_limit="171.00"/>
                    <measurement group_id="O8" value="58.00" lower_limit="48.00" upper_limit="91.42"/>
                    <measurement group_id="O9" value="62.22" lower_limit="48.00" upper_limit="153.10"/>
                    <measurement group_id="O10" value="70.18" lower_limit="67" upper_limit="72.76"/>
                    <measurement group_id="O11" value="57.5" lower_limit="45.4" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AC-Emax - Hemoglobin</title>
        <description>Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug</description>
        <time_frame>0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>AC-Emax - Hemoglobin</title>
          <description>Absolute maximum of hemoglobin (AC-Emax - hemoglobin) after single injection of study drug</description>
          <units>gramm per liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="3.00" upper_limit="11.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.00" upper_limit="22.00"/>
                    <measurement group_id="O3" value="7.00" lower_limit="5.00" upper_limit="9.00"/>
                    <measurement group_id="O4" value="9.00" lower_limit="8.00" upper_limit="15.00"/>
                    <measurement group_id="O5" value="9.00" lower_limit="6.00" upper_limit="21.00"/>
                    <measurement group_id="O6" value="6.00" lower_limit="4.00" upper_limit="26.00"/>
                    <measurement group_id="O7" value="10.00" lower_limit="8.00" upper_limit="10.00"/>
                    <measurement group_id="O8" value="10.50" lower_limit="3.00" upper_limit="12.00"/>
                    <measurement group_id="O9" value="9.00" lower_limit="8.00" upper_limit="13.00"/>
                    <measurement group_id="O10" value="11.00" lower_limit="8.00" upper_limit="13.00"/>
                    <measurement group_id="O11" value="10.5" lower_limit="9.00" upper_limit="12.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale</title>
        <description>visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome</description>
        <time_frame>intraoperative</time_frame>
        <population>In second period of study, when healthy volunteers received BCD-131 in optimal dose, visual analoge scale was not applied (by protocol)</population>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale</title>
          <description>visual analog scale Minimum value - 0, Maximum value -10, Higher scores mean worse outcome</description>
          <population>In second period of study, when healthy volunteers received BCD-131 in optimal dose, visual analoge scale was not applied (by protocol)</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O5" value="2" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O6" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O7" value="2" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O8" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O9" value="2" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
        <description>Total incidence of adverse events (AE)/ serious adverse events (SAE)</description>
        <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events</title>
          <description>Total incidence of adverse events (AE)/ serious adverse events (SAE)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="4"/>
                    <measurement group_id="O11" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Local Reactions</title>
        <description>Incidence of administration site reactions</description>
        <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Local Reactions</title>
          <description>Incidence of administration site reactions</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AE/SAE 3-4 Grade CTCAE</title>
        <description>Incidence of Grade 3-4 AEs and SAEs.</description>
        <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AE/SAE 3-4 Grade CTCAE</title>
          <description>Incidence of Grade 3-4 AEs and SAEs.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Early Withdrawal Due to AE</title>
        <description>Frequency of early withdrawals due to AEs and SAEs</description>
        <time_frame>from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Early Withdrawal Due to AE</title>
          <description>Frequency of early withdrawals due to AEs and SAEs</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Binding Antibodies to BCD-131</title>
        <description>Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131</description>
        <time_frame>0, day 50 post-dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O2">
            <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O3">
            <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O4">
            <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O5">
            <title>BCD-131, 1.70 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O6">
            <title>BCD-131, 2.25 mcg/kg SC</title>
            <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O7">
            <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
          </group>
          <group group_id="O8">
            <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
          </group>
          <group group_id="O9">
            <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
            <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
          </group>
          <group group_id="O10">
            <title>BCD-131, Optimal Dose, Intravenously</title>
            <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
          </group>
          <group group_id="O11">
            <title>BCD-131, Optimal Dose, Subcutaneously</title>
            <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Binding Antibodies to BCD-131</title>
          <description>Incidence of Binding antibodies to BCD-131 on Day 50 after a single injection of BCD-131</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from the first administration of the first dose of the drug up to the end of follow up period (28 days after the last administration of the drug)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-131, 0.05 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.05 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E2">
          <title>BCD-131, 0.15 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.15 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E3">
          <title>BCD-131, 0.40 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.40 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E4">
          <title>BCD-131, 1.05 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 1.05 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E5">
          <title>BCD-131, 1.70 mcg/kg SC</title>
          <description>Healthy volunteers received BCD-131 in a dose 1.70 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E6">
          <title>BCD-131, 2.25 mcg/kg SC</title>
          <description>Healthy volunteers received BCD-131 in a dose 2.25 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E7">
          <title>BCD-131, 4.45 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 4.45 mcg/kg subcutaneously
BCD-131</description>
        </group>
        <group group_id="E8">
          <title>Mircera®, 1.20 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received Mircera in a dose 1.20 mcg/kg subcutaneously
Mircera®</description>
        </group>
        <group group_id="E9">
          <title>Aranesp®, 0.45 mcg/kg Subcutaneously</title>
          <description>Healthy volunteers received BCD-131 in a dose 0.45 mcg/kg subcutaneously
Aranesp®</description>
        </group>
        <group group_id="E10">
          <title>BCD-131, Optimal Dose, Intravenously</title>
          <description>Healthy volunteers received BCD-131 in optimal dose - 2,75 mcg/kg determined on first stage of clinical trial intravenously
BCD-131</description>
        </group>
        <group group_id="E11">
          <title>BCD-131, Optimal Dose, Subcutaneously</title>
          <description>Healthy volunteers will receive BCD-131 in optimal dose - 2,75 mcg/kgdetermined on first stage of clinical trial subcutaneously
BCD-131</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>monocytes count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>basophils increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>eosinophils increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutrophiles decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leucocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yulia Linkova Medical Director</name_or_title>
      <organization>Biocad</organization>
      <phone>+7 (495) 992 66 28 ext 930</phone>
      <email>linkova@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

